0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Baudax Bio
Its shares trade under the ticker BXRXQ. It has been listed since 14 November 2019. In the fiscal year to 30 September 2022, it reported revenue of $1.3m and a net loss of $58.8m. At that date it held total assets of $10.0m and shareholders' equity of −$24.2m.
Baudax Bio, Inc. operates as a pharmaceutical company. The company is headquartered in Malvern, Pennsylvania. The company went IPO on 2019-11-14. The firm is focused on developing and commercializing products for hospital and related acute care settings. The firm's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. The company is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. The company is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 14 Nov 2019
- Employees
- 9
- Website
- baudaxbio.com ↗
Leadership
Pay as last reported
- Mr. Wayne WeismanIndependent Chairman of the Board$113,591
- Ms. Geraldine HenwoodPresident, Chief Executive Officer, Director, since 2019$663,224
- Ms. Jillian DilmorePrincipal Financial Officer, Principal Accounting Officer$254,978
- Ms. Natalie McandrewInterim Chief Financial Officer
- Dr. Yong Chan KimDirector
- Mr. William AshtonIndependent Director$99,974
- Dr. Arnold BaskiesIndependent Director$82,474
- Mr. Winston ChurchillIndependent Director$95,107
- Mr. Andrew DrechslerIndependent Director$89,974
- Mr. Mike MoyerInvestor Relations, since 2023
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 52
- Environment
- 54
- Social
- 73
- Governance
- 30
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Baudax Bio's lead product ANJESO injection targets hospital acute care pain management with COX-2 selectivity.
- The company's pipeline includes two neuromuscular blocking agents and a specific reversal agent for surgical use.
- Baudax Bio focuses on Treg-based cell therapies for autoimmune diseases, expanding its therapeutic scope.
Weaknesses
- Baudax Bio has only 9 full-time employees, limiting operational capacity.
- The company's IPO in 2019 may indicate limited financial resources for development.
- Baudax Bio operates from Malvern, Pennsylvania, a location with no major pharmaceutical hubs.
Opportunities
- ANJESO injection could expand into international markets beyond US hospital settings.
- The pipeline of NMBAs and reversal agents may attract partnerships with surgical device companies.
- Treg-based cell therapies for autoimmune diseases present a growing market opportunity.
Threats
- Competition from established pharmaceutical companies in the COX-2 pain management sector.
- Regulatory hurdles for new NMBAs and reversal agents in surgical applications.
- Potential delays in clinical trials for Treg-based cell therapies for autoimmune diseases.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.